Vaxart, INC

Vaxart, Inc. announced a reorganization of its Board of Directors' Nominating and Governance and Compensation Committees, with new chairs appointed effective August 1, 2026.

Vaxart stockholders approved director elections and auditor ratification but rejected executive compensation in an advisory vote at the company's annual meeting.

Vaxart announced topline 12-month safety data from its Phase 2b trial, showing no vaccine-related serious adverse events in its oral COVID-19 vaccine candidate compared to an mRNA comparator.

Vaxart, Inc. has entered into a cooperation agreement with a stockholder group to resolve a proxy contest, leading to board and corporate governance enhancements.

Vaxart has modified its BARDA contract to reflect a reduced trial scope, securing $345 million in total funding to advance data analysis for its oral COVID-19 vaccine.

Vaxart, Inc. has filed preliminary proxy materials and issued a letter to shareholders urging support for its director nominees in an upcoming election, while also addressing a dissident shareholder's nominations.

Vaxart, Inc. reported Q1 2026 results, showing increased revenue driven by government contracts, while continuing development of its oral COVID-19 and norovirus vaccine candidates.

Vaxart reported a significant increase in government contract revenue and a reduced net loss for Q3 2025, bolstered by a new $30 million upfront deal with Dynavax, which alleviates prior going concern doubts, despite its recent Nasdaq delisting and reduced scope of a key BARDA contract.

Vaxart reports increased Q2 2025 revenue and reduced net loss, but faces a stop work order on its pivotal COVID-19 vaccine trial and Nasdaq delisting, raising significant going concern doubts.

Vaxart, Inc. announces its financial results for the first quarter of 2025, highlighting revenue growth driven by government contracts and providing updates on its vaccine development programs.

Vaxart's Q3 2024 report highlights progress in clinical trials and financial activities, including a significant government contract and capital raises.

Vaxart's second quarter 2024 results show increased revenue from government contracts and a net loss, alongside progress in clinical trials and strategic funding agreements.

Vaxart, Inc. filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding directors, executive compensation, and corporate governance.

Vaxart's 2024 10-K filing reveals a year of progress in vaccine development, but also highlights significant uncertainties surrounding its COVID-19 program due to potential funding termination.

Vaxart's 10-K filing details the structure of its common stock, anti-takeover provisions, and compliance with securities regulations.

Kevin Finney, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

James B Breitmeyer, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

Elaine J Heron, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

W. Mark Watson, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

David E. Wheadon, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

Vaxart, Inc. reports that Director W. Mark Watson acquired 10,000 shares of common stock on May 22, 2026.

Vaxart, Inc. has adjourned its 2025 special meeting of stockholders to September 19, 2025, to allow more time for consideration of recent board and governance changes, and potential future disclosures.

Vaxart management strongly urges stockholders to approve a reverse stock split to regain NASDAQ compliance, citing benefits for capital access, visibility, and investor protection.

Vaxart, Inc. announced a virtual fireside chat to discuss its reverse stock split proposal, which has received support from ISS and Glass Lewis, aimed at regaining Nasdaq compliance.

Vaxart's CEO urges stockholders to approve a reverse stock split to regain Nasdaq listing, citing benefits for investor access and financing, despite a recent Stop Work Order on its COVID-19 vaccine trial.

Vaxart, Inc. is seeking stockholder approval for a reverse stock split, ranging from 1-for-5 to 1-for-20, aimed at increasing its share price to meet Nasdaq's minimum bid requirement and avoid delisting.

Vaxart's Founder and CSO, Dr. Sean Tucker, released a video urging stockholders to vote for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule.

Vaxart, Inc. has registered up to 32.9 million shares of common stock for resale by Lincoln Park Capital Fund, LLC to support its ongoing clinical development programs.

Sio Capital Management, LLC has filed a Schedule 13G, reporting a passive beneficial ownership of 2.45% of Vaxart, Inc.'s common stock as of March 31, 2025.

Sio Capital Management, LLC has reported a 5.06% beneficial ownership stake in Vaxart, Inc., holding 11,515,315 shares as of December 31, 2024, in a Schedule 13G filing.